0000000000398217

AUTHOR

Alexander Marx

showing 22 related works from this author

CD73 Overexpression in Podocytes: A Novel Marker of Podocyte Injury in Human Kidney Disease

2021

The CD73 pathway is an important anti-inflammatory mechanism in various disease settings. Observations in mouse models suggested that CD73 might have a protective role in kidney damage

Male0301 basic medicinePathologyCCR2podocyte030232 urology & nephrologyGene ExpressionKidneyPodocyte0302 clinical medicineFocal segmental glomerulosclerosisMedicineMinimal change diseaseBiology (General)5'-NucleotidaseSpectroscopyAged 80 and overKidneymedicine.diagnostic_testPodocytesGlomerulonephritisGeneral MedicineMiddle AgedComputer Science ApplicationsChemistryProteinuriaminimal change diseasemedicine.anatomical_structureImmunohistochemistryFemaleKidney DiseasesAdultmedicine.medical_specialtyQH301-705.5Receptors CCR2GPI-Linked ProteinsImmunofluorescenceArticleCatalysisInorganic Chemistry03 medical and health sciencesHumansPhysical and Theoretical ChemistryQD1-999Molecular BiologyAgedbusiness.industryOrganic Chemistrymedicine.disease030104 developmental biologyGene Expression RegulationCD73CCR2businessBiomarkersInternational Journal of Molecular Sciences
researchProduct

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

2022

Abstract This overview of the fifth edition of the WHO classification of thymic epithelial tumors (including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]), mediastinal germ cell tumors, and mesenchymal neoplasms aims to (1) list established and new tumor entities and subtypes and (2) focus on diagnostic, molecular, and conceptual advances since publication of the fourth edition in 2015. Diagnostic advances are best exemplified by the immunohistochemical characterization of adenocarcinomas and the recognition of genetic translocations in metaplastic thymomas, rare B2 and B3 thymomas, and hyalinizing clear cell carcinomas. Advancements at the molecular and tumor biolog…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsThymomaThymomaAdenocarcinomaNeuroendocrine tumorsWorld Health OrganizationThymic carcinoma03 medical and health sciences0302 clinical medicineGerm cell tumormedicineHumansGerm cell tumor; NET G3; Thymic carcinoma; Thymic neuroendocrine tumor; Thymoma; WHO classificationThymic carcinoma030304 developmental biologyWHO classification0303 health sciencesbusiness.industryMesenchymal stem cellMediastinumMediastinumThymus Neoplasmsmedicine.disease3. Good healthThymic neuroendocrine tumorGerm Cellsmedicine.anatomical_structureOncology030220 oncology & carcinogenesisGerm cell tumorsNET G3businessClear cellGerm cellJournal of Thoracic Oncology
researchProduct

The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

2009

Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) inhibits T-cell activation and interleukin-2 (IL-2) production. The PTPN22(gain-of-function)+1858T(+) genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG). The disease association and the requirement of IL-2/IL-2 receptor signaling for intrathymic, negative T-cell selection have suggested that these genotypes may weaken T-cell receptor (TCR) signaling and impair the deletion of autoreactive T cells. Evidence for this hypothesis is missing. Thymoma-associated MG, which depends on intratumorous generation and export of mature autoreactive CD4(+) T cells, is a model of au…

AdultMalemedicine.medical_specialtyThymomaAdolescentGenotypeThymomaImmunologyBiologymedicine.disease_causePolymorphism Single NucleotideWhite PeopleAutoimmunityPTPN22Young AdultAntigens CDInternal medicineMyasthenia GravisCentral tolerance inductionGeneticsmedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseReceptorGenetics (clinical)AgedAged 80 and overT-cell receptorProtein Tyrosine Phosphatase Non-Receptor Type 22Thymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyInterleukin-2FemaleCentral toleranceGenes & Immunity
researchProduct

A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer His…

2020

Abstract Introduction In-depth genomic characterization of thymic epithelial tumors (TETs), comprising thymomas and thymic carcinomas (TCs), failed to identify targetable mutations and suggested unique biology of TETs, including KIT expression in most TCs. Recently, tuft cell–like medullary thymic epithelial cells were identified in the murine thymus, and our reanalysis of the published gene expression data revealed that these cells express KIT. In addition, recently, a minor subset of SCLCs with tuft cell–like features was described. Methods We interrogated mRNA expression data from our tumor cohorts (N = 60) and publicly available, independent data sets from TETs and NSCLC (N = 1199) for …

0301 basic medicinePulmonary and Respiratory MedicineLung NeoplasmsThymomaurologic and male genital diseasesmedicine.disease_cause03 medical and health sciencesMice0302 clinical medicinemedicineAnimalsHumansLung cancerThymic carcinomaThymic Squamous Cell Carcinomaurogenital systembusiness.industryCancerThymus Neoplasmsmedicine.diseasePhenotypeSmall Cell Lung Carcinomafemale genital diseases and pregnancy complications3. Good health030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchCarcinoma Squamous CellImmunohistochemistryTuft cellbusinessCarcinogenesisJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
researchProduct

A CTLA4high genotype is associated with myasthenia gravis in thymoma patients

2005

Myasthenia gravis (MG) in thymoma patients depends critically on intratumorous generation and export of mature autoreactive CD4+ T cells. Why non-MG thymomas fail to produce CD4+ T cells is unknown. We studied three single-nucleotide polymorphisms of the cytotoxic T-lymphocyte–associated antigen 4(CTLA4) gene in thymoma patients, nonthymoma early-onset MG patients, and control subjects. Surprisingly, the CTLA4high genotype +49A/A, which is protective against several autoimmune diseases, exerted a prominent predisposing effect to paraneoplastic MG in thymoma patients. The unusual disease association with a CTLA4high genotype implies a unique pathogenesis of paraneoplastic MG, with high CTLA4…

AdultMaleThymomaAdolescentGenotypeThymomaDisease Associationchemical and pharmacologic phenomenaPolymorphism Single NucleotidePathogenesis03 medical and health sciences0302 clinical medicineGene FrequencyAntigenAntigens CDhemic and lymphatic diseasesMyasthenia GravisGenotypeHumansMedicineCytotoxic T cellCTLA-4 AntigenChildGeneAgedDemography030304 developmental biology0303 health sciencesbusiness.industryThymus NeoplasmsMiddle Agedmedicine.diseaseAntigens DifferentiationMyasthenia gravis3. Good healthNeurologyImmunologyFemaleNeurology (clinical)business030215 immunologyAnnals of Neurology
researchProduct

Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis

2013

Autoimmune associations in myasthenia gravis (MG)-patients and their relatives have not been re-assessed since their separation into early- or late-onset MG (EOMG, LOMG), or thymoma-associated MG. Here, we analysed 226 EOMG-, 97 LOMG-, and 150 thymoma-patients for autoimmune disorders in themselves and their relatives. From 283 of them sera were tested for different organ- and non-organ-specific autoantibodies (autoAbs) by immunofluorescence test (IFT) and ELISA; genotyping was performed in 213 patients. Relatives with autoimmune disorders were reported by more patients with EOMG (40% of 210) than LOMG (20% of 89; p0.01) than thymomas (8% of 150; p0.001). In 150 genotyped EOMG-females, the …

AdultMaleAdolescentGenotypeThymomaAnti-nuclear antibodyImmunologyPTPN22Young AdultPrimary biliary cirrhosisPopulation GroupsMyasthenia GravismedicineHumansImmunology and AllergyAge of OnsetChildAgedAutoantibodiesAged 80 and overProtein Tyrosine Phosphatase Non-Receptor Type 2Neuromyelitis opticabusiness.industryMultiple sclerosisAutoantibodyGeneral MedicineMiddle Agedmedicine.diseaseMuscle StriatedMyasthenia gravisPedigreeOrgan SpecificityChild PreschoolRheumatoid arthritisImmunologyAdrenal CortexFemalebusinessHuman Immunology
researchProduct

The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens.

2008

The thymus is believed to play an important role in the pathogenesis of myasthenia gravis (MG). The 80% of MG patients with anti-acetylcholine receptor autoantibodies fall into three clinical subgroups: 1) thymoma; 2) early-onset MG (<age of 40; EOMG) and 3) late-onset (LOMG; onset after 40). Thymectomy is widely used in EOMG, but its benefits have not been established in randomized controlled trials. A multicenter international trial (MGTX) currently seeks to determine whether thymectomy reduces corticosteroid requirements, and to look for correlations with thymic histology. We here describe the validated, standardized histological workup and reporting system used in this trial.

AdultMaleAgingPathologymedicine.medical_specialtyThymomaAdolescentThymomamedicine.medical_treatmentImmunologyThymus GlandThymus Extractslaw.inventionSex FactorsAtrophyRandomized controlled triallawMyasthenia GravismedicineHumansImmunology and AllergyChildRandomized Controlled Trials as TopicThymus extractThymus Neoplasmbusiness.industryAge FactorsAutoantibodyReproducibility of ResultsThymus NeoplasmsThymectomymedicine.diseaseImmunohistochemistryMyasthenia gravisThymectomyNeurologyFemaleNeurology (clinical)businessJournal of neuroimmunology
researchProduct

Expression of the Acetylcholine Receptor α-Subunit Gene is Associated with Paraneoplastic Myasthenia Gravis in Mixed Thymoma

2000

Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction [1]. The muscular AChR has been extensively characterized [2], but the etiology of MG is still obscure. Whether the muscular AChR or another (auto)antigen plays a role during the initiation of MG is unknown [3]. The muscular AChR is a pentameric ion channel composed of four different subunits. The α-subunit contains the acetylcholine binding site and the main epitopes recognized by MG autoantibodies [2]. The human muscle AChR α-subunit exists as two isoforms, P3A- and P3A+ [4]. This is a result of alternative splicing of the P3A exon located betwee…

Gene isoformanimal structuresChemistryAlternative splicingmusculoskeletal systemmedicine.diseasemedicine.disease_causeMolecular biologyNeuromuscular junctionMyasthenia gravisAcetylcholine bindingMolecular mimicrymedicine.anatomical_structureNicotinic agonistmedicinetissuesAcetylcholine receptor
researchProduct

Neurofilament is an autoantigenic determinant in myasthenia gravis

1999

Intratumorous expression of a 153-kd protein (p153), which contains an acetylcholine receptor-like epitope, is the only tumor marker described to date that significantly associates with thymoma in paraneoplastic myasthenia gravis (MG). Here, we report that p153 is identical to the midsize neurofilament, as verified by immunohistochemistry, immunofluorescence, and western blot analysis. Furthermore, the acetylcholine receptor-like epitope of the midsize neurofilament (NF-M) was identified by peptide epitope mapping. We also show, using T-cell proliferation assays, a significantly increased response of intratumorous T cells to a recombinant midsize neurofilament fragment in thymoma patients w…

Pathologymedicine.medical_specialtyThymomamusic.instrumentNeurofilamentmedicine.diagnostic_testBiologymedicine.diseaseImmunofluorescenceFollicular hyperplasiaMyasthenia gravisEpitopeNeurologyhemic and lymphatic diseasesmedicineImmunohistochemistryNeurology (clinical)musicAcetylcholine receptorAnnals of Neurology
researchProduct

Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS‐1)

2007

Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in ‘central’ tolerance in both humans and mice. However, while inactivating AIRE mutations result in the ‘autoimmune polyendocrinopathy syndrome type 1’ (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable…

AdultMaleThymomaAdolescentThymomaAntibodies NeoplasmThymus Glandmedicine.disease_causeAutoantigensAutoimmune DiseasesPathology and Forensic MedicineAutoimmunity03 medical and health sciences0302 clinical medicineAntigens NeoplasmInterferonMyasthenia GravismedicineHumansPolyendocrinopathies AutoimmuneAgedAutoantibodies030304 developmental biologyAged 80 and over0303 health sciencesbiologybusiness.industryAutoantibodyThymus NeoplasmsMiddle AgedAutoimmune regulatormedicine.diseaseImmunohistochemistryMyasthenia gravisNeoplasm Proteins3. Good healthThymic Tissue030220 oncology & carcinogenesisInterferon Type IImmunologybiology.proteinCytokinesFemaleAntibodybusinessTranscription Factorsmedicine.drugThe Journal of Pathology
researchProduct

GTF2I Mutation in Thymomas: Independence From Racial-Ethnic Backgrounds. An Indian/German Comparative Study

2021

Thymomas are the most frequent adult mediastinal cancers. Their etiology is unknown and their pathogenesis poorly understood. Racial, ethnic and environmental factors influence tumorigenesis in many cancers, but their role in thymomas remains unclear to date. In this study that included pretreatment thymoma cases from India and Germany (n = 37 and n = 77, respectively) we compared i) the prevalence of the thymoma-specific chromosome 7 c.74146970T &amp;gt; A mutation of the GTF2I gene in type A and AB thymomas; ii) epidemiological features; and iii) the frequency of myasthenia gravis (MG). Due to a known predominance of GTF2I mutation in A and AB histotypes, we included only a marginal numbe…

AdultMaleOncologymedicine.medical_specialtyCancer ResearchThymomaThymomaEthnic groupIndiaracial-ethnic factorsPathology and Forensic MedicinePathogenesisTranscription Factors TFII03 medical and health sciences0302 clinical medicineGermanyInternal medicineEpidemiologymedicineHumansOriginal ResearchAged030304 developmental biologyChromosome 7 (human)myasthenia gravis0303 health sciencesbusiness.industryPathology and Oncology ArchiveGTF2I mutationThymus NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisRace Factors3. Good healthOncology030220 oncology & carcinogenesisMutationCohortEtiologyepidemiologyFemalebusinessPathology and Oncology Research
researchProduct

Low Levels of Acetylcholine Receptor Delta-Subunit Message and Protein in Human Thymus Suggests the Occurrence of ‘Triplet Receptors’ in Thymic Myoid…

2000

Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction [1]. The muscular AChR has been extensively characterized [2], but whether the muscular AChR plays a role during the initiation of MG is unknown [3]. The muscular AChR is a pentameric ion channel composed of 4 different subunits [2, 4]. The fetal AChR expressed during intrauterine life and after denervation of adult muscle exhibits an α2βδγ composition, while the adult AChR expressed after birth in innervated muscle exhibits an α2βδγ composition [4]. The α-subunit contains the main epitopes recognized by MG autoantibodies [2]. The human muscle AChR…

DenervationGene isoformmedicine.medical_specialtyanimal structuresThymomaBiologymusculoskeletal systemmedicine.diseaseMolecular biologyEpitopeMyasthenia gravisNeuromuscular junctionEndocrinologymedicine.anatomical_structureInternal medicinemedicineReceptortissuesAcetylcholine receptor
researchProduct

Accuracy and Safety of Ultrasound-Guided Core Needle Biopsy of Soft Tissue Tumors in an Outpatient Setting: A Sarcoma Center Analysis of 392 Consecut…

2021

Simple Summary In patients with unclear soft tissue lesions, treatment planning largely depends on histology. Core needle biopsy is the diagnostic standard in these cases. The aim of this retrospective study was to investigate accuracy and safety of ultrasound guided core needle biopsy at a tertiary referral center. We show that ultrasound guided biopsy was feasible as a one stop shop procedure in an outpatient setting in 87.6% of the cases. The rate of conclusive biopsies was 88.5%. After surgical resection, the dignity, tumor type and histopathological grading of the biopsy matched one of the resection specimens in 97.2%, 92.7% and 92.5% of the cases, respectively. Major complications occ…

Core needlesafetyCancer Researchmedicine.medical_specialtyConcordancecore needle biopsyArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBiopsymedicineOutpatient settingRC254-282medicine.diagnostic_testaccuracybusiness.industrySoft tissue sarcomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensSoft tissuemedicine.diseaseUltrasound guided3. Good healthOncology030220 oncology & carcinogenesissoft tissue sarcomaRadiologySarcomabusinessCancers
researchProduct

cFLIPoverexpression in T cells in thymoma‐associated myasthenia gravis

2015

OBJECTIVE: The capacity of thymomas to generate mature CD4+ effector T cells from immature precursors inside the tumor and export them to the blood is associated with thymoma-associated myasthenia gravis (TAMG). Why TAMG(+) thymomas generate and export more mature CD4+ T cells than MG(-) thymomas is unknown. METHODS: Unfixed thymoma tissue, thymocytes derived thereof, peripheral blood mononuclear cells (PBMCs), T-cell subsets and B cells were analysed using qRT-PCR and western blotting. Survival of PBMCs was measured by MTT assay. FAS-mediated apoptosis in PBMCs was quantified by flow cytometry. NF-κB in PBMCs was inhibited by the NF-κB-Inhibitor, EF24 prior to FAS-Ligand (FASLG) treatment …

0303 health sciencesThymomamedicine.diagnostic_testApoptosis Inhibitorbusiness.industryGeneral Neurosciencemedicine.diseasePeripheral blood mononuclear cellMyasthenia gravisFlow cytometryBlot03 medical and health sciences0302 clinical medicineApoptosishemic and lymphatic diseasesImmunologymedicineCancer researchMTT assayNeurology (clinical)businessResearch Articles030304 developmental biology030215 immunologyAnnals of Clinical and Translational Neurology
researchProduct

Thymus pathology observed in the MGTX trial

2012

The MGTX trial is the first prospective, randomized clinical trial that aims to evaluate the impact of extended transsternal thymectomy on myasthenic symptoms, prednisone requirements, and quality of life in patients with nonthymomatous, anti-acetylcholine receptor autoantibody-positive myasthenia gravis (MG). Here, we give an overview of the rationale of thymectomy and the standardized macroscopic and histopathological work-up of thymectomy specimens as fixed in MGTX standard operating procedures, including the grading of thymic lymphofollicular hyperplasia and the morphometric strategy to assess thymic involution.

Pathologymedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicineHistory and Philosophy of ScienceRandomized controlled triallawPrednisonemedicineProspective cohort studyGrading (tumors)Thymic involutionbusiness.industryGeneral NeuroscienceHyperplasiamedicine.diseaseMyasthenia gravis3. Good healthThymectomybusiness030217 neurology & neurosurgerymedicine.drugAnnals of the New York Academy of Sciences
researchProduct

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

2014

Abstract Late-onset myasthenia gravis (LOMG) has become the largest MG subgroup, but the underlying pathogenetic mechanisms remain mysterious. Among the few etiological clues are the almost unique serologic parallels between LOMG and thymoma-associated MG (TAMG), notably autoantibodies against acetylcholine receptors, titin, ryanodine receptor, type I interferons or IL-12. This is why we checked LOMG patients for two further peculiar features of TAMG – its associations with the CTLA4 high/gain-of-function  +49A/A genotype and with increased thymic export of naive T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas. We analyzed genomic DNA from 116 …

Malemedicine.medical_specialtyGenotypeThymomaT-LymphocytesImmunologyDNA Mutational AnalysisRecent Thymic EmigrantLate onsetCell CountThymus GlandBiologyPeripheral blood mononuclear cellWhite PeopleGene FrequencyInternal medicineGenotypeMyasthenia GravismedicineImmune ToleranceImmunology and AllergyHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGenetic Association StudiesAgedPeripheral tolerance inductionAged 80 and overPolymorphism GeneticThymocytesT-cell receptor excision circlesAutoantibodyCell DifferentiationThymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyFemaleJournal of autoimmunity
researchProduct

Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases.

2021

Thymic hyperplasia (TH) with lymphoepithelial sialadenitis (LESA)-like features (LESA-like TH) has been described as a tumor-like, benign proliferation of thymic epithelial cells and lymphoid follicles. We aimed to determine the frequency of lymphoma and autoimmunity in LESA-like TH and performed retrospective analysis of cases with LESA-like TH and/or thymic MALT-lymphoma. Among 36 patients (21 males) with LESA-like TH (age 52 years, 32&ndash

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyPure red cell aplasia610 Medicine & healthautoimmune diseaselymphomathymitismedicine.disease_causelcsh:RC254-282SclerodermaArticleAutoimmunitysurgery03 medical and health sciences0302 clinical medicinethymusimmune system diseaseshemic and lymphatic diseasesmedicineddc:610Autoimmune diseasebusiness.industryLESAimagingHyperplasialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseLESA; autoimmune disease; imaging; lymphoma; myasthenia; pathology; surgery; thymic epithelial tumor; thymitis; thymusSialadenitisMyasthenia gravis3. Good healthLymphomamyasthenia030104 developmental biologyOncologythymic epithelial tumor030220 oncology & carcinogenesis570 Life sciences; biologypathologybusiness
researchProduct

A Follicular Dendritic Cell Sarcoma of the Mediastinum With Immature T Cells and Association With Myasthenia Gravis

2010

Follicular dendritic cell (FDC) sarcoma is a very rare neoplasm showing morphologic and phenotypic features of FDCs. It occurs primarily in lymph nodes but also in extranodal sites. So far, there have been no reports on FDC sarcoma associated with myasthenia gravis. In the following we will present a case of an FDC tumor of the mediastinum associated with paraneoplastic myasthenia gravis in a 39-year-old man. The tumor contained a major proportion of immature T cells, which may be connected to this patient's very unusual clinical presentation with autoimmune phenomena. Extranodal FDC sarcomas still seem hardly noticed, and their clinical and pathologic characteristics remain to be better de…

AdultMalePathologymedicine.medical_specialtyT-LymphocytesDendritic Cell Sarcoma FollicularMediastinal NeoplasmsFollicular cellPathology and Forensic MedicineAzathioprineMyasthenia GravisBiomarkers TumormedicineHumansAntigen-presenting cellFollicular dendritic cellsbusiness.industryMediastinumDendritic cellThymectomymedicine.diseaseImmunohistochemistryMyasthenia gravismedicine.anatomical_structureFollicular dendritic cell sarcomaSurgeryLymph NodesSarcomaAnatomybusinessImmunosuppressive AgentsAmerican Journal of Surgical Pathology
researchProduct

Thymoma and paraneoplastic myasthenia gravis

2010

Paraneoplastic autoimmune diseases associate occasionally with small cell lung cancers and gynecologic tumors. However, myasthenia gravis (MG) occurs in at least 30% of all patients with thymomas (usually present at MG diagnosis). These epithelial neoplasms almost always have numerous admixed maturing polyclonal T cells (thymocytes). This thymopoiesis-and export of mature CD4(+)T cells-particularly associates with MG, though there are rare/puzzling exceptions in apparently pure epithelial WHO type A thymomas. Other features potentially leading to inefficient self-tolerance induction include defective epithelial expression of the autoimmune regulator (AIRE) gene and/or of major histocompatib…

ThymomaThymomaT-LymphocytesGenes MHC Class IIImmunologyCellThymus Glandmedicine.disease_causeAutoantigensAutoimmunityhemic and lymphatic diseasesMyasthenia GravisHumansImmunology and AllergyMedicineLymphopoiesisPolyendocrinopathies AutoimmuneAutoantibodiesMHC class IIbiologybusiness.industryLymphopoiesisFOXP3Epithelial Cellsmedicine.diseaseAutoimmune regulatorMyasthenia gravismedicine.anatomical_structureImmunoglobulin GImmunologybiology.proteinbusinessParaneoplastic Syndromes Nervous SystemTranscription FactorsAutoimmunity
researchProduct

The Autoimmune Regulator AIRE in Thymoma Biology: Autoimmunity and Beyond

2010

Thymomas are tumors of thymic epithelial cells. They associate more often than any other human tumors with various autoimmune diseases; myasthenia gravis is the commonest, occurring in 10-50% of thymoma patients, depending on the World Health Organization-defined histologic subtype. Most thymomas generate many polyclonal maturing T lymphocytes but in disorganized microenvironments Failure to induce self-tolerance may be a key factor leading to the export of potentially autoreactive CD4 progeny, thus predisposing to autoimmune diseases. Normally, the master Autoimmune Regulator promotes expression of peripheral tissue-restricted antigens such as insulin by medullary thymic epithelial cells a…

Pulmonary and Respiratory MedicineThymomaThymomamedicine.medical_treatmentAutoimmunitymedicine.disease_causeWorld healthAutoimmune DiseasesAutoimmunityAntigenAIREhemic and lymphatic diseasesAPS-1HumansMedicineMyasthenia gravisbusiness.industryInsulinThymus NeoplasmsAutoimmune regulatormedicine.diseaseMyasthenia gravisOncologyImmunologybusinessAPECEDTranscription FactorsJournal of Thoracic Oncology
researchProduct

Selective loss of regulatory T cells in thymomas

2004

Myasthenia gravis (MG) is the prime autoimmune manifestation of thymomas. We investigated the generation of T cells with a regulatory phenotype (T(R)) in thymomas with and without associated MG. In patients with MG(+) thymomas, maturation and export of T(R) cells but not of other T-cell subsets was significantly reduced. We conclude that imbalance between effector and regulatory T cells in thymomas may be involved in modulation of onset and/or severity of MG.

Programmed cell deathThymomabusiness.industryEffectorCellular differentiationchemical and pharmacologic phenomenaT lymphocytemedicine.diseasePhenotypeClonal deletionMyasthenia gravissurgical procedures operativeNeurologyhemic and lymphatic diseasesImmunologyCancer researchMedicineNeurology (clinical)businessneoplasmsAnnals of Neurology
researchProduct

Cancer Acidity and Hypertonicity Contribute to Dysfunction of Tumor-Associated Dendritic Cells: Potential Impact on Antigen Cross-Presentation Machin…

2020

Macrophages (M) and dendritic cells (DC), major players of the mononuclear phagocyte system (MoPh), are potent antigen presenting cells that steadily sense and respond to signals from the surrounding microenvironment, leading to either immunogenic or tolerogenic outcomes. Next to classical MHC-I/MHC-II antigen-presentation pathways described in the vast majority of cell types, a subset of MoPh (CD8+, XCR1+, CLEC9A+, BDCA3+ conventional DCs in human) is endowed with a high competence to cross-present external (engulfed) antigens on MHC-I molecules to CD8+ T-cells. This exceptional DC function is thought to be a crucial crossroad in cytotoxic antitumor immunity and has been extensively studie…

0301 basic medicineCancer Researchcancer acidityReviewMajor histocompatibility complexlcsh:RC254-28203 medical and health sciences0302 clinical medicineAntigenCytotoxic T celltumor microenvironmentAntigen-presenting cellcross-presentationTumor microenvironmentbiologyChemistryCross-presentationMononuclear phagocyte systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensWarburg effectCell biology030104 developmental biologyOncologyhyperosmolarity030220 oncology & carcinogenesisbiology.proteinCancers
researchProduct